急性早幼粒细胞白血病诊断与复发时的突变图谱
该研究采用包含31个髓系基因的NGS panel检测44例初诊和31例复发APL患者的骨髓样本,并用定制NGS-RNA panel分析PML和RARA基因突变。初诊时中位2个突变可预测复发,≤1个突变者复发风险显著更低(HR 0.046;95%CI 0.011-0.197;
要点
- ATRA/ATO后复发的APL患者中PML基因为优先突变靶点。
核心结论
- 初诊时NGS分析可能为APL治疗决策提供信息,包括对不利突变谱病例选择替代治疗。
研究设计与样本
- 采用包含31个髓系基因的NGS panel检测44例初诊和31例复发APL患者的骨髓样本,并用定制NGS-RNA panel研究PML和RARA基因突变。
主要发现
- ATRA/ATO后复发者PML基因为优先突变靶点。
临床怎么用
- 初诊时NGS分析可能为APL治疗决策提供信息,包括对不利突变谱病例选择替代治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the high probability of cure of patients with acute promyelocytic leukemia (APL), mechanisms of relapse are still largely unclear. Mutational profiling at diagnosis and/or relapse may help to identify APL patients needing frequent molecular monitoring and early treatment intervention. Using an NGS approach including a 31 myeloid gene-panel, we tested BM samples of 44 APLs at the time of diagnosis, and of 31 at relapse. Mutations in PML and RARA genes were studied using a customized-NGS-RNA panel. Patients relapsing after ATRA-chemotherapy rarely had additional mutations (P = .009). In patients relapsing after ATRA/ATO, the PML gene was a preferential mutation target. We then evaluated the predictive value of mutations at APL diagnosis. A median of two mutations was detectable in 9/11 patients who later relapsed, vs one mutation in 21/33 patients who remained in CCR (P = .0032). This corresponded to a significantly lower risk of relapse in patients with one or less mutations (HR 0.046; 95% CI 0.011-0.197; P < .0001). NGS-analysis at the time of APL diagnosis may inform treatment decisions, including alternative treatments for cases with an unfavorable mutation profile.
引用
- Iaccarino L, Ottone T, Alfonso V, et al. Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. Am J Hematol. 2019. PMID: 31292998. doi:10.1002/ajh.25573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。